{
    "clinical_study": {
        "@rank": "133018", 
        "brief_summary": {
            "textblock": "To assess the dose-related antiviral effects of SC-48334 and zidovudine (AZT) administered\n      in combination or individually in HIV-1 positive patients with 200 - 500 CD4+ cells/mm3. To\n      determine the safety of escalating doses of SC-48334 when administered in combination with\n      any of three doses of AZT to symptomatic HIV-1 positive patients with 200 - 500 CD4+\n      cells/mm3, and to assess the pharmacokinetics of the two drugs, given separately and in\n      combination."
        }, 
        "brief_title": "Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  CD4 cell count 200 - 500 cells/mm3.\n\n          -  Prior therapy with 12 - 48 weeks of AZT.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Clinically significant diarrhea without definable cause (> 3 liquid stools per day\n             for more than 7 days within 6 months prior to study entry).\n\n          -  Diarrhea, as above, with known non-HIV-related cause occurring within 1 month prior\n             to study entry.\n\n          -  Symptoms meeting CDC criteria for AIDS classification.\n\n          -  Fever as a constitutional sign of HIV disease (> 38.5 degrees C persisting for more\n             than 14 consecutive days or for more than 15 days in any given 30-day period prior to\n             study entry).\n\n          -  Malignancies, other than basal cell carcinoma and Kaposi's sarcoma (provided patient\n             has fewer than 10 Kaposi's sarcoma lesions, no non-skin lesions, and no requirement\n             for systemic treatment).\n\n          -  Significant organ dysfunction.\n\n          -  Known hypersensitivity to SC-48334 or AZT or related compounds.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Any investigational drug other than SC-48334.\n\n          -  Any anti-HIV drug other than AZT.\n\n          -  Cancer chemotherapy.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of cataracts or known increased risk of cataract formation.\n\n          -  Known hypersensitivity to SC-48334 or AZT or related compounds.\n\n          -  History of lactose intolerance.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Prior SC-48334.\n\n          -  Cancer chemotherapy within 6 months prior to study entry.\n\n          -  Treatment with any investigational drug or any drug with anti-HIV activity, other\n             than AZT, within 30 days prior to study entry.\n\n        Prior Treatment:\n\n        Excluded:\n\n        Whole-body irradiation within 6 months prior to study entry. Current use of illicit\n        substances, or abuse of alcohol, which would limit compliance with the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002079", 
            "org_study_id": "057B", 
            "secondary_id": "NS8-91-02-009"
        }, 
        "intervention": [
            {
                "intervention_name": "Butyldeoxynojirimycin", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Zidovudine", 
                "Miglustat"
            ]
        }, 
        "keyword": [
            "Zidovudine", 
            "1-Deoxynojirimycin"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Dr Marcus Conant"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tarzana", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91356"
                    }, 
                    "name": "Shared Med Research Foundation"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33140"
                    }, 
                    "name": "Stratogen of South Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33614"
                    }, 
                    "name": "Saint Joseph's Hosp / Infectious Disease Rsch Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30327"
                    }, 
                    "name": "West Paces Clinical Research Incoporated"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15218"
                    }, 
                    "name": "Dr Samuel W Golden"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75216"
                    }, 
                    "name": "Dallas Veterans Administration Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76104"
                    }, 
                    "name": "Dr Daniel Barbero"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77004"
                    }, 
                    "name": "Park Plaza Hosp"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "7905523", 
            "citation": "Fischl MA, Resnick L, Coombs R, Kremer AB, Pottage JC Jr, Fass RJ, Fife KH, Powderly WG, Collier AC, Aspinall RL, et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr. 1994 Feb;7(2):139-47."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002079"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "G D Searle", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1993"
    }, 
    "geocoordinates": {
        "Dallas Veterans Administration Med Ctr": "32.803 -96.77", 
        "Dr Daniel Barbero": "32.725 -97.321", 
        "Dr Marcus Conant": "37.775 -122.419", 
        "Dr Samuel W Golden": "40.441 -79.996", 
        "Park Plaza Hosp": "29.76 -95.369", 
        "Saint Joseph's Hosp / Infectious Disease Rsch Institute": "27.951 -82.457", 
        "Shared Med Research Foundation": "34.149 -118.551", 
        "Stratogen of South Florida": "25.791 -80.13", 
        "West Paces Clinical Research Incoporated": "33.749 -84.388"
    }
}